• CRISPR Therapeutics presented Phase 1b results for CTX310 in severe hypertriglyceridemia today at the American Heart Association Scientific Sessions 2026.
• The investigational gene-editing therapy substantially reduced triglycerides following a single treatment, with reductions maintained during longer follow-up.
• Treatment was well tolerated, with no treatment-related serious adverse events or clinically relevant liver enzyme elevations.
• The FDA recently granted CTX310 Regenerative Medicine Advanced Therapy designations for severe hypertriglyceridemia and elevated LDL cholesterol; Phase 1b trials remain ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090916PRIMZONEFULLFEED9873094) on November 09, 2026, and is solely responsible for the information contained therein.